Hence, our study supports co-targeting of the integrin-FAK pathway and BRD4 as a promising line of synthetic lethal-type therapy for NSCLC, regardless of the state of EGFR or KRAS. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.